Literature DB >> 31772972

Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer.

William M Mendenhall1, Gabriella Glassman1, Christopher G Morris1, Joseph A Costa2, Christopher R Williams2, Stephanie E Harris2, Stephen E Mandia2, Bradford S Hoppe1, Randal H Henderson1, Curtis M Bryant1, R Charles Nichols1, Nancy P Mendenhall1.   

Abstract

PURPOSE: To determine the incidence of a bacterial urinary tract infection (UTI) necessitating hospitalization after transrectal placement of fiducial markers prior to proton radiotherapy (RT) for prostate cancer.
MATERIALS AND METHODS: Six hundred sixty six patients returning for follow up after proton RT consented to participate in this institutional review board (IRB) approved study. Patients were queried whether they required hospitalization within 1 month of transrectal placement of fiducial markers. Patients were treated with proton RT between August 2006 and December 2014. Median International Prostate Symptom Score (IPSS) was 7. Sixty four patients (9.6%) had diabetes, 9 patients (1.4%) had chronic obstructive pulmonary disease, 6 patients (0.9%) had prior bladder surgery, 7 patients (1.1%) had a transurethral prostatectomy within 3 months, and 549 patients (82.4%) had a course of antibiotics within 6 months. Fifty five patients (8.3%) were taking tamsulosin, 16 patients (2.4%) were taking finasteride, and 62 patients (9.3%) were taking saw palmetto. The interval between the most recent prostate biopsy prior to fiducial placement and fiducial marker placement was less than 6 months in 609 patients (91.4%). No patient had a prior recent rectal culture.
RESULTS: Ten patients (1.5%) developed a bacterial UTI necessitating hospitalization after transrectal placement of fiducial markers. A bacterial UTI occurred in 3 (0.7%) of 440 patients treated from 2006 to 2012 and in 7 (3.1%) of 226 patients treated from 2013 to 2014. Univariate analysis of potential association of a bacterial UTI with the following parameters revealed: IPSS less than or greater than the median (p=0.3400), diabetes (p=0.6099), tamsulosin (p=0.9999), saw palmetto (p=0.0093), interval between prostate biopsy and placement of fiducials (p=0.9999), year of treatment (p=0.0363), and antibiotics within 6 months (p=0.2233). A bacterial UTI was observed in 4 (6.5%) of 62 patients who were taking saw palmetto versus 6 (1.0%) of 604 patients who were not taking this medication. The incidence of a bacterial UTI between 2006 and 2012 was 3 (0.7%) of 440 patients and from 2013 to 2014 was 7 (3.1%) of 226 patients. Multivariate analysis revealed that the likelihood of a bacterial UTI was increased in patients taking saw palmetto (p=0.0044) and those treated in 2013-2014 (p=0.0303).
CONCLUSION: The incidence of a bacterial UTI requiring hospitalization after transrectal placement of fiducial markers prior to proton RT was 1.5% and was impacted by taking saw palmetto and year of treatment. Patients treated during 2013 and 2014 had a significantly higher risk of a bacterial UTI requiring hospitalization. © Copyright 2016 International Journal of Particle Therapy.

Entities:  

Keywords:  fiducial markers; prostate cancer; urinary tract infection

Year:  2016        PMID: 31772972      PMCID: PMC6871580          DOI: 10.14338/IJPT-16-00007.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  21 in total

1.  Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis?

Authors:  D Steensels; K Slabbaert; L De Wever; P Vermeersch; H Van Poppel; J Verhaegen
Journal:  Clin Microbiol Infect       Date:  2011-09-29       Impact factor: 8.067

2.  Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers.

Authors:  Henkjan J Huisman; Jurgen J Fütterer; Emile N J T van Lin; Arjan Welmers; Tom W J Scheenen; Jorn A van Dalen; Andries G Visser; J A Witjes; Jelle O Barentsz
Journal:  Radiology       Date:  2005-06-27       Impact factor: 11.105

3.  Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers.

Authors:  J Wu; T Haycocks; H Alasti; G Ottewell; N Middlemiss; M Abdolell; P Warde; A Toi; C Catton
Journal:  Radiother Oncol       Date:  2001-11       Impact factor: 6.280

4.  Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study.

Authors:  Alexandre Campeggi; Idir Ouzaid; Evanguelos Xylinas; Philippe Lesprit; Andras Hoznek; Dimitri Vordos; Claude-Clément Abbou; Laurent Salomon; Alexandre de la Taille
Journal:  Int J Urol       Date:  2013-08-01       Impact factor: 3.369

5.  Planning and implementing an implanted fiducial programme for prostate cancer radiation therapy.

Authors:  A Thompson; C Fox; F Foroudi; C Styles; K H Tai; R Owen; M Laferlita
Journal:  J Med Imaging Radiat Oncol       Date:  2008-08       Impact factor: 1.735

6.  Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers.

Authors:  David Skarsgard; Pat Cadman; Ali El-Gayed; Robert Pearcey; Patricia Tai; Nadeem Pervez; Jackson Wu
Journal:  Radiat Oncol       Date:  2010-06-10       Impact factor: 3.481

7.  Early infectious complications with transponder placement for external beam radiation therapy for prostate cancer.

Authors:  Ryan K Berglund; Osama Zaytoun; Richard Thousand; Kevin Stephans; Rahul Tendulkar; Eric A Klein; J Stephen Jones
Journal:  BJU Int       Date:  2012-02-16       Impact factor: 5.588

8.  Implantation of fiducial markers for image guidance in prostate radiotherapy: patient-reported toxicity.

Authors:  S Igdem; H Akpinar; G Alço; F Agaçayak; S Turkan; S Okkan
Journal:  Br J Radiol       Date:  2009-06-08       Impact factor: 3.039

9.  Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: complication rate and risk factors.

Authors:  Johan F Langenhuijsen; Emile N J T van Lin; Lambertus A Kiemeney; Lisette P van der Vight; Gill M McColl; Andries G Visser; J Alfred Witjes
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-23       Impact factor: 7.038

10.  Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy.

Authors:  Chao Qi; Michael Malczynski; Anthony J Schaeffer; Grace Barajas; Robert B Nadler; Marc H Scheetz; Teresa R Zembower
Journal:  J Urol       Date:  2013-05-30       Impact factor: 7.450

View more
  1 in total

1.  Cost-Effectiveness of the Use of Gold Anchor™ Markers in Prostate Cancer.

Authors:  Martina Lundqvist; Lars-Åke Levin
Journal:  Cureus       Date:  2020-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.